Stool

DIAGNOSTIC_TEST5 trials

Conditions

CancerClostridium DifficileCrohn DiseaseMetastatic Lung CancerNon-squamous Lung CancerUlcerative Colitis (UC)

Unknown Phase

Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis

NCT01973465

OSF Healthcare SystemClostridium Difficile

Start: 2013-09-30End: 2014-09-30Target: 10Updated: 2013-10-31

Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach

RecruitingNCT04567446

Gustave Roussy, Cancer Campus, Grand ParisCancer

Start: 2018-01-22End: 2024-12-31Target: 1100Updated: 2024-06-12

Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study

CompletedNCT04804137

University Hospital, ToursMetastatic Lung Cancer, Non-squamous Lung Cancer

Start: 2021-05-03End: 2023-07-31Updated: 2024-01-17

AI-enabled Endoscopic Prediction of Post-operative Recurrence in Crohn's Disease

RecruitingNCT06505304

University College CorkCrohn Disease

Start: 2024-05-01End: 2026-05-31Target: 225Updated: 2024-07-18

AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis

RecruitingNCT06709209

University College CorkUlcerative Colitis (UC)

Start: 2024-11-04End: 2027-09-30Target: 300Updated: 2024-12-03

Journal of Crohn s and Colitis2026-01-01

P0313 A new intestinal ultrasound score to assess post-operative recurrence in Crohn’s disease: the PROSPER-IUS

Journal of Crohn s and Colitis2026-01-01

P0429 Redefining Ulcerative Colitis Assessment Through Multimodal Virtual Chromoendoscopy: The MONET Study

Journal of Crohn s and Colitis2026-01-01

P0194 The PROSPER endoscopic score: An advanced imaging tool for early detection of post-operative recurrence in Crohn’s disease

Journal of Crohn s and Colitis2026-01-01

Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief Report.

2025-10-29

8The actionable microbial gut checkpoint MAdCAM-1 in patients with advanced renal cell carcinoma

The Oncologist2025-10-01

Association of intestinal exfoliome and Prevotellaceae with toxicity and clinical outcome during immune-checkpoint blockade.

Journal of Clinical Oncology2025-05-281 citations

Gut dysbiosis as a potential guide for immunotherapy (dis)continuation after 2 years in non-small cell lung cancer: A mono-institutional, multi-omic assessment.

Journal of Clinical Oncology2025-05-28

Abstract 3813: Multipronged approach identifying new hallmarks of antibiotics-mediated immunosuppression in a prospective trial of cancer immunotherapy

Cancer Research2025-04-211 citations

Abstract 1173: Desaminotyrosine contributes to the anticancer effect of fecal microbial transplantation during immune checkpoint blockade in mice and patients

Cancer Research2025-04-21

Impact of microbiota specific circulating memory T cells in response to immunotherapy.

Journal of Clinical Oncology2024-06-013 citations

Correlation of gut dysbiosis biomarkers and peripheral thyroid hormones conversion in patients with (pts) advanced lung cancer.

Journal of Clinical Oncology2024-06-01

Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).

Journal of Clinical Oncology2023-06-015 citations

The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups and correlates with gut microbiota (GM) in patients with advanced renal cell carcinoma (RCC).

Journal of Clinical Oncology2023-02-202 citations

Intestinal <i>Akkermansia muciniphila</i> predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.

Journal of Clinical Oncology2021-05-207 citations

Stool

Sponsors

Conditions

Unknown Phase

Related Papers